Drugs /

jnj-74699157

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Clinical Trials

View Clinical Trials for jnj-74699157

Jnj-74699157 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating jnj-74699157, 1 is phase 1 (0 open).

KRAS G12C is the most frequent biomarker inclusion criterion for jnj-74699157 clinical trials.

Malignant solid tumor is the most common disease being investigated in jnj-74699157 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Jnj-74699157
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating jnj-74699157 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
jnj74699157, jnj 74699157, g12c mutant kras protein inhibitor jnj-74699157, ars-3248, ars3248, ars 3248, krasg12c inhibitor jnj-74699157
Drug Target(s) [2]:
KRAS
NCIT ID [1]:
C167157

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.